Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance

AbCellera Biologics IncTrade
NEOS S&P 500 High Income ETFTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs NEOS S&P 500 High Income ETF — how do they compare? AbCellera Biologics Inc trades at $9.07 (market cap $2.99B), while NEOS S&P 500 High Income ETF trades at $54.15. Which is the better fit depends on your goals.

ABCLSPYI
Market Cap
$2.99B
Sector
HealthIncome / Options Overlay
52-Week High
$9.76$54.19
52-Week Low
$2.78$47.98
Enterprise Value
$2.58B

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About NEOS S&P 500 High Income ETF

SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.

Read more on SPYI